Defect‐Rich MoO 3‐X @CuO 2 Nanosheets Mediated Ultrasound‐Enhanced Cuproptosis Antibacterial Activity and M2 Macrophage Reprogramming for Optimizing Diabetic Wound Repairment
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202500601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Yutang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Liquid-Solid Structural Evolution & Processing of Materials (Ministry of Education), School of Materials Science and Engineering, …. Hauptthemen laut MEDLINE: Wound Healing, Copper, Anti-Bacterial Agents, Molybdenum. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Diabetic wounds are often plagued by persistent bacterial infections, which exacerbate inflammation and impair healing processes such as collagen deposition and fibroblast migration. Conventional antibiotic therapies frequently prove ineffective and can even hinder wound repair. To address these challenges, biodegradable MoO 3‐x @CuO 2 ion disruptors (MCO IDs) that for comprehensive diabetic wound treatment is developed. The MCO IDs generate a burst of multimodal reactive oxygen species (ROS) that effectively penetrate bacterial defenses and disrupt redox homeostasis. Released copper ions induce proteotoxic stress‐like bacterial death by targeting lipoylated and iron–sulfur cluster proteins. Transcriptomic and metabolomic analyses reveal that this mechanism systematically inhibits bacterial energy metabolism and gene expression, effectively suppressing proliferation. Following bacterial eradication, the released copper ions promote macrophage repolarization to the M2 phenotype, mitigating chronic inflammation and stimulating wound healing. Furthermore, to enhance wound management, a portable wound dressing (PVA‐MCO) is fabricated by electrospinning polyvinyl alcohol (PVA) incorporating the MCO IDs. In vivo studies demonstrate that the PVA‐MCO dressing effectively eliminates pathogenic bacteria and promotes collagen deposition, angiogenesis, and epithelialization, thereby accelerating diabetic wound healing. This multifaceted therapeutic strategy offers a promising solution for managing persistent infections and promoting diabetic wound repair.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Liquid-Solid Structural Evolution & Processing of Materials (Ministry of Education), School of Materials Science and Engineering, Shandong University, Jinan, Shandong, 250061, P. R. China.
- Beijing Jishuitan Hospital, Captial Medical University, Beijing, 100035, P. R. China.
- Beijing Traumotology and Orthopaedics Research Center, Beijing, 100035, P. R. China.
- The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250033, P. R. China.
ORCID-Profile: Yanyan Jiang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, Y., Wang, Y., Wang, Y., Wang, F., Chang, F., & Jiang, Y. (2025). Defect‐Rich MoO 3‐X @CuO 2 Nanosheets Mediated Ultrasound‐Enhanced Cuproptosis Antibacterial Activity and M2 Macrophage Reprogramming for Optimizing Diabetic Wound Repairment. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500601
Vancouver
Li Y, Wang Y, Wang Y, Wang F, Chang F, Jiang Y. Defect‐Rich MoO 3‐X @CuO 2 Nanosheets Mediated Ultrasound‐Enhanced Cuproptosis Antibacterial Activity and M2 Macrophage Reprogramming for Optimizing Diabetic Wound Repairment. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500601
BibTeX
@article{Li2025,
author = {Li, Yutang and Wang, Yi and Wang, Yandong and Wang, Fenglong and Chang, Fei and Jiang, Yanyan},
title = {Defect‐Rich MoO 3‐X @CuO 2 Nanosheets Mediated Ultrasound‐Enhanced Cuproptosis Antibacterial Activity and M2 Macrophage Reprogramming for Optimizing Diabetic Wound Repairment},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202500601}
}
EUVIMED